Funding and Grants

Current Funding Opportunities

MCW Cancer Center Pilot Funding ProgramNovember 2017 RFA is Open Now

LOIs due on November 29th. 

Marquette + MCWCC Multi-PI Grant RFA

LOIs due on December 1st. 

Grant support resources are now available from the MCW Cancer Center.

National Cancer Institute (NCI)

Open AllClose All
  Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01)

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Applications due November 27, 2017

  Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R21)

The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Applications due November 27, 2017

  Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01 - Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Applications due November 27, 2017

  Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed) (Deadline: 11/27/17)

Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R21 - Clinical Trial Not Allowed)

The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Applications due November 27, 2017

  NCI Outstanding Investigator Award (R35) (Deadline: 11/28/17)

NCI Outstanding Investigator Award (R35)

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA.

It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

Applications due November 28, 2017

  New Informatics Tools and Methods to Enhance US Cancer Surveillance and Research (UG3/UH3) (Deadline: 11/30/17)

New Informatics Tools and Methods to Enhance US Cancer Surveillance and Research (UG3/UH3)

The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA seeks applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration cancer registry data and to expand the data items collected. Applications must be built on partnership with U.S. population-based central cancer registries (a partnership must involve at least two different registries). Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research.

Applications due November 30, 2017

  Notice of Intent to Publish a Funding Opportunity Announcement for ‘Programs to Increase Diversity among Individuals Engaged in Health Related Research’ (PRIDE) Summer Institutes (R25)/(U24) (Deadline: FOA December 2017 (expected); Due date March 2018)

Notice of Intent to Publish a Funding Opportunity Announcement for ‘Programs to Increase Diversity among Individuals Engaged in Health Related Research’ (PRIDE) Summer Institutes (R25)/(U24)

The National Heart, Lung, and Blood Institute intends to publish a Funding Opportunity Announcement (FOA) to solicit applications for the Programs to Increase Diversity among Individuals Engaged in Health Related Research (PRIDE) Summer Institutes. The PRIDE Summer Institutes programs aim to enhance the diversity of the biomedical, behavioral and clinical research workforce through provision of research education and mentoring experiences for junior faculty from underrepresented backgrounds, at NHLBI-funded summer institutes across the nation.

This Notice is being provided to allow potential applicants sufficient time to develop responsive applications. The FOA is expected to be published in December 2017 with an application due date in March 2018 and will utilize the R25 mechanism. Details of this planned FOA are provided below.

FOA Expected Release Date: December 2017 with a due date of March 2018

  Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R01 Clinical Trial Not Allowed) (Deadline: 12/4/17)

Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R01 Clinical Trial Not Allowed)

The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

Applications due December 4, 2017

  Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R21 Clinical Trial Not Allowed) (Deadline: 12/4/17)

Collaborative Minority Health and Health Disparities Research with Tribal Epidemiology Centers (R21 Clinical Trial Not Allowed)

The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

Applications due December 4, 2017

  Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (R21)- Now updated to include NCI’s participation (Deadline: 12/11/17)

Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries (R21)- Now updated to include NCI’s participation

The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on a) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission; b) reducing the impact of stigma on adolescent and/or youth health; c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections; d) reducing effects of stigma on and/or by family members or caregivers of PLWH; and e) innovative and improved stigma measurement in the context of implementation of an intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to initiate exploratory studies to determine the feasibility of stigma interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

In addition to research areas listed in the Funding Opportunity Description, NCI is interested in applications that address the following scientific gaps:

  • Evidence-based studies to reduce cancer stigma associated with strategies for behavioral changes of modifiable risk factors (e.g., smoking, obesity, alcohol use, diet) in people living with HIV/AIDS (PLWH);
  • Develop interventions to recognize and address stigma among healthcare providers, home care specialists, and caregivers for cancer patients living with HIV/AIDS;
  • Studies that enhance our understanding of the role stigma plays in accessing cancer screening and care as well as its impact on survivorship;
  • Develop and test tools that reduce stigma for PLWH and cancer that enhance palliation and end-of-life decisions across the care continuum; and
  • Develop interventions to improve patient - healthcare provider communication and educate hospice workers, home care specialists, and caregivers.

Applications due December 11, 2017

  AACR-Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award (Deadline: 12/12/17)

AACR-Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award

Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this jointly-supported award is to fund a physician-scientist during the transition from a fellowship program to a faculty appointment. Research projects are restricted to translational cancer research.

Applications due December 12, 2107

  Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01) (Deadline: 12/19/17)

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-17-050, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area(s) designated as a scientific priority(ies) by the Blue Ribbon Panel (BRP): Recommendation (B) (PDF) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system.

This FOA solicits U01 applications for discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.), while the companion FOA, RFA-CA-17-050, solicits multi-component U54 Center applications. Successful applicants from both FOAs will become members of the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), which will address and implement the BRP recommendations.

Applications due December 19, 2017

  Pediatric Immunotherapy Translational Science Network (PI-TSN)(U01) (Deadline: 12/19/17)

Pediatric Immunotherapy Translational Science Network (PI-TSN)(U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-17-050, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area(s) designated as a scientific priority(ies) by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system.

This FOA solicits U01 applications for discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.), while the companion FOA, RFA-CA-17-050, solicits multi-component U54 Center applications. Successful applicants from both FOAs will become members of the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), which will address and implement the BRP recommendations.

Applications due December 19, 2017

  Pediatric Immunotherapy Translational Science Network (PI-TSN)(U54) (Deadline: 12/19/17)

Pediatric Immunotherapy Translational Science Network (PI-TSN)(U54)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications.

Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

Applications due December 19, 2017

  Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54) (Deadline: 12/19/17)

Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications.

Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

Applications due December 19, 2017

  Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24) (Deadline: 1/5/18)

Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research.

The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers.

The DRSCs are designed to target the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Establish a network of multi-disciplinary research teams to study mechanisms of tumor resistance and sensitivity and develop innovative anti-cancer therapy strategies. The Coordinating Center to be established under this FOA will facilitate the activities of the DRSCs and help integrate the results of their studies.

Applications due January 5, 2018

  High or Medium Priority AIDS Research on Non-AIDS-Defining or AIDS-Defining Cancers (R01) (Deadlines: 1/7/18; 5/7/18)

High or Medium Priority AIDS Research on Non-AIDS-Defining or AIDS-Defining Cancers (R01)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

This FOA encourages research efforts that will identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers; and provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

Components of Participating Organizations:

  • National Cancer Institute (NCI)
  • National Institute of Dental and Craniofacial Research (NIDCR)

Applications due January 7, 2018; May 7, 2018

  "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21) (Deadlines: 1/7/18; 5/7/18)

"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R21)

The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or acquired immunodeficiency syndrome (AIDS), particularly the non-AIDS defining malignancies which are now a leading cause of death in HIV-infected individuals.

This FOA encourages high or medium priority AIDS research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in populations with an underlying HIV infection.

This FOA encourages research efforts that will (i) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers and (ii) provide information on the clinical outcomes of such cancers in the HIV-infected population. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

Applications due January 7, 2018; May 7, 2018

  Limited Competition: Lasker Clinical Research Scholars Transition Award (R00) (Rolling Deadline: 9/25/17-1/7/18)

Limited Competition: Lasker Clinical Research Scholars Transition Award (R00)

The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.

Rolling Deadline: Applications due September 25, 2017-January 7, 2018

  Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) (Deadline: 1/9/18)

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." 

Applications due January 9, 2018

  Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01) (Deadline: 1/9/18)

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

This Funding Opportunity Announcement (FOA) invites U01 application for projects aimed at identifying best practices to improve case ascertainment of hereditary cancers, with the goal of improving prevention and detection.

Applications due January 9, 2018

  Simulation Modeling and Systems Science to Address Health Disparities (R01Clinical Trial Not Allowed) (Deadlines: 1/10/18; 6/6/18)

Simulation Modeling and Systems Science to Address Health Disparities (R01Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities.

Applications due January 10, 2018; June 6, 2018

  Cardiovascular and Pulmonary Research on E-Cigarettes (R01) (Deadline: 1/16/18)

Cardiovascular and Pulmonary Research on E-Cigarettes (R01)

The purpose of this funding opportunity announcement (FOA) is to stimulate research on cardiovascular and pulmonary physiologic and health effects of electronic cigarette (e-cigarette) exposure. This FOA invites applications addressing the effects of e-cigarettes on the cardiovascular and pulmonary systems, alone or in combination. Studies involving clinical populations, animal models and/or cell preparations would all be considered responsive. Research may examine the effects of the whole e-cigarette aerosol or of individual components or constituents. Research may also examine where aerosols, components, or constituents deposit in the airways and resulting heart and/or lung consequences.

Applications due January 16, 2018

  Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01) (Deadline: 1/16/18)

Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.

Applications due January 16, 2018

  Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01) (Deadline: 1/16/18)

Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01)

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.

Applications due January 16, 2018

  Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24) (Deadline: 1/16/18)

Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.

Applications due January 16, 2018

  Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (DMRC) (U24) (Deadline: 1/16/18)

Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (DMRC) (U24)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.

Applications due January 16, 2018

  Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01) (Deadline: 1/17/18)

Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot InitiativeSM that is intended to accelerate cancer research. The purpose of this FOA is to promote research on developing the descriptive, inferential, and graphical statistical methods for data generated in clinical trials including Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) items. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Accelerate research that can identify approaches to monitor and manage patient-reported symptoms.

Applications due January 17, 2018

  Coordinating Center for Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (U24) (Deadline: 1/17/18)

Coordinating Center for Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (U24)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of comprehensive symptom management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.

The consortium will consist of a Coordinating Center (to be supported by this U24 FOA) and Research Centers (to be funded under a companion UM1 FOA, RFA-CA-17-042).

The Coordinating Center is expected to:

  1. Provide oversight and coordination of the Research Centers and the Steering Committee,
  2. Ensure standardized, harmonized data collection across the Research Centers,
  3. Establish processes for pooled analyses.

The Coordinating Center is expected to interact with the Research Centers and provide oversight and management of collaborative activities within the entire consortium. Collaborative activities will be supported scientifically and coordinated administratively and logistically by the Coordinating Center.

Research Centers are responsible for the deployment and evaluation of the symptom assessment and management system using implementation science approaches.

Applications due January 17, 2018

  Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (UM1) (Deadline: 1/17/18)

Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (UM1)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of integrated symptom monitoring and management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.

The consortium will consist of three Research Centers (to be supported by this UM1 FOA) and a Coordinating Center (to be funded under a companion U24 FOA, RFA-CA-17-043).

Each Research Center is expected to:

  1. Deploy an integrated symptom monitoring and management system in a group of clinical practices, and
  2. Test the impact of that system on patient outcomes, cancer treatment delivery, and healthcare utilization using a randomized design.

The Research Centers will be expected to interact with the Coordinating Center and engage in collaborative activities with the entire consortium. Collaborative activities will be supported scientifically and coordinated administratively and logistically by the Coordinating Center.

Applications due January 17, 2018

  Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24) (Deadline: 1/18/18)

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS): Coordinating Center (U24)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.

The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) Program will provide an evidence base for multilevel interventions that increase rates of colorectal cancer (CRC) screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of CRC on the United States (U.S.) population.

The ACCSIS Program will support a U24 Coordinating Center (under this FOA) and UG3/UH3 phased award research projects (companion RFA-CA-17-038).

The ACCSIS Coordinating Center will facilitate coordination across the ACCSIS Research Projects (UG3/UH3 phased award supported under companion RFA-CA-17-038); provide administrative support to the ACCSIS Program; assist with identification and collection of common data elements; support the evaluation of locally-developed innovative approaches to increase CRC screening, follow-up, and referral-to-care rates; and develop and coordinate data sharing plans.

Applications due January 18, 2018

  Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3) (Deadline: 1/18/18)

Accelerating Colorectal Cancer Screening and follow-up through Implementation Science (ACCSIS)(UG3/UH3)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. This purpose of this FOA is to promote research in colorectal cancer (CRC) screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based approaches.

The Accelerating Colorectal Cancer Screening and Follow-up through Implementation Science (ACCSIS) program will provide an evidence base for multilevel interventions that increase rates of CRC screening, follow-up, and referral-to-care, and best practices for how multilevel interventions can be scaled-up to reduce the burden of colorectal cancer on the United States (U.S.) population.

The ACCSIS Program will support UG3/UH3 phased award research projects (under this FOA) and a U24 Coordinating Center (companion RFA-CA-17-039).

The UG3/UH3 projects in response to this FOA must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development of one-year, milestone-driven planning phase (UG3), with possible rapid transition to the second phase (UH3) for clinical trials. UH3s will be awarded after administrative review of eligible UG3s that have met the scientific milestones and feasibility requirements necessary for the UH3 phase, depending on availability of funds.

Applications due January 18, 2018

  Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20) (Deadline: 1/18/18)

Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.

Applications due January 18, 2018

  Human Tumor Atlas Network: Data Coordinating Center (U24) (Deadline: 1/18/18)

Human Tumor Atlas Network: Data Coordinating Center (U24)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

Through this FOA, the National Cancer Institute (NCI) invites cooperative agreement applications to develop a Human Tumor Atlas Network (HTAN) Data Coordinating Center (DCC). The HTAN-DCC will have two major areas of responsibility: (1) Data Standards, Storage, Analysis, and Dissemination; and, (2) Consortium Coordination and Outreach. The HTAN-DCC will collect, store, curate, and disseminate all data, metadata, analysis and visualization tools, computational models, and completed atlases generated by the HTAN. Additionally, the DCC will lead the development of common data elements, data and metadata standards, clinical and epidemiological data requirements, and data processing pipelines. The DCC will also coordinate HTAN activities including in-person and virtual Network Steering Committee meetings and working groups. Finally, the HTAN-DCC will promote collaboration and communication among HTAN Investigators and the broader research community and coordinate the Network outreach activities.

Applications due January 18, 2018

  Human Tumor Atlas Research Centers (U2C) (Deadline: 1/18/18)

Human Tumor Atlas Research Centers (U2C)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

For the purposes of this FOA, a comprehensive human tumor atlas is defined as the multidimensional molecular, cellular, and morphological mapping of human cancers, complemented with critical spatial information (at the molecular, cellular, and/or tissue level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem.

Tumor atlases will be developed by the Human Tumor Atlas Network (HTAN), which will include the Human Tumor Atlas (HTA) Research Centers (this FOA), the Pre-Cancer Atlas (PCA) Research Centers (solicited under companion RFA-CA-17-035), an HTAN Data Coordinating Center (solicited under companion RFA-CA-17-036), and an HTAN Tissue Coordinating Center (anticipated to be solicited in Fiscal Year 2019).

Through this FOA, the National Cancer Institute (NCI) invites cooperative agreement (U2C) applications for HTA Research Centers, a collaborative research initiative that aims to build tumor atlases through the dynamic multiparameter characterizations of cancerous lesions across high-priority cancer types, including those that disproportionally effect minority and underserved patients.

The Human Tumor Atlas (HTA) Research Centers will each lead construction of at least one, but no more than three, organ-specific human tumor atlases that describe overall cellular and molecular architecture of critical transitions in tumorigenesis for use by the research and clinical communities. The data and analytical tools generated by the HTA Research Centers will be made available to the research community through the activities of the HTAN Data Coordinating Center (U24).

Applications due January 18, 2018

  Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54) (Deadline: 1/18/18)

Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54)

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

Applications due January 18, 2018

  Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54) (Deadline: 1/18/18)

Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54)

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

PDXNet will encompass four PDTCs (to be supported by RFA-CA-17-003), a single PDX Data Commons and Coordinating Center (PDCCC) (to be supported by RFA-CA-17-004) and two M-PDTC (to be supported by this FOA).

The main goals for M-PDTCs include:

Development of racially/ethnically diverse PDX models and methods for preclinical testing of single agents and drug combinations; and

Conducting studies of response of PDX models, primarily from racially/ethnically diverse populations, to develop novel therapeutic strategies using both newly established and existing well-characterized PDX models.

It is expected that the outcomes of PDXNet research, in general, will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI's Experimental Therapeutic Clinical Trials Network (ETCTN).

Furthermore, the research to be conducted by the M-PDTCs should advance the understanding of therapeutic outcome disparities seen among diverse racial/ethnic minority populations.

Applications due January 18, 2018

  Pre-Cancer Atlas (PCA) Research Centers (U2C) (Deadline: 1/18/18)

Pre-Cancer Atlas (PCA) Research Centers (U2C)

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic, multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors.

The tumor atlases will be developed by the Human Tumor Atlas Network (HTAN), which will include the Pre-Cancer Atlas (PCA) Research Centers (this FOA), the Human Tumor Atlas (HTA) Research Centers (solicited under companion RFA-CA-17-034), an HTAN Data Coordinating Center (solicited under companion RFA-CA-17-036), and an HTAN Tissue Coordinating Center (anticipated to be developed in Fiscal Year 2019).

Through this FOA, the National Cancer Institute (NCI) invites applications for the PCA Research Centers, a collaborative research initiative that aims to construct comprehensive, dynamic, high-resolution, multidimensional, multiparametric, temporal and scalable atlases of pre-cancerous lesions and their surrounding microenvironment for select organ sites, including high-priority cancers that disproportionally affect minority and underserved patients. A deeper understanding of the transition from pre-malignant to malignant state as a function of time will allow the development of more precise risk stratification methods and effective early intervention strategies.

Each PCA Research Center will lead the construction of at least one human pre-cancer atlas for use by the research and clinical communities. The data and analytical tools generated by the PCA Research Centers will be made available to the research community through the aid of the HTA Data Coordinating Center.

Applications due January 18, 2018

  NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1) (Deadline: 1/19/18)

NCI National Clinical Trials Network - Network Group Integrated Translational Science Centers (UG1)

This Funding Opportunity Announcement (FOA) is one of six FOAs that support the comprehensive effort by the National Cancer Institute (NCI) to provide the infrastructure for the conduct of national clinical trials through the National Clinical Trials Network (NCTN). The primary goal of the NCTN is the conduct of multi-center, late-phase, clinical treatment trials (i.e., randomized phase 2 and phase 3 trials) and advanced imaging trials across a broad range of cancers, modalities, and diverse patient populations as part of the NCI's overall clinical research program for adults, adolescents and young adults, and children with cancer. The NCTN also conducts, as necessary, preliminary studies needed for development of definitive trials, especially umbrella/basket trials and rare tumor trials, when an extensive, national patient catchment area is required.

Applications due January 19, 2018

  Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25) (Deadline: 1/25/18)

Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25)

Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, as well as the cause and reduction of cancer health disparities in accordance with the overall mission of the NCI

Applications due September 25, 2017 or January 25, 2018

  Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2018, 2019, and 2020 (P50 Clinical Trial Required) (Deadline: 1/25/18)

Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2018, 2019, and 2020 (P50 Clinical Trial Required)

This funding opportunity announcement (FOA) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPOREs). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a related group of cancers.

For the purpose of this FOA, cancers derived from the same organ system (i.e., a group of organs that perform a common function) are considered related. Examples of such organ systems include gastrointestinal, endocrine and other biological systems. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers sustained and promoted by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

Applications due January 25, 2018

  Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01) (Deadline: 1/31/18)

Population Assessment of Tobacco and Health (PATH) Biospecimen Access (X01)

The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigan’s National Addiction & HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Research’s (ICPSR) website.

Applications due January 31, 2018

  Examination of Survivorship Care Planning Efficacy and Impact (R01 Clinical Trial Optional) (Deadline: 2/5/18)

Examination of Survivorship Care Planning Efficacy and Impact (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Applications due February 5, 2018

  Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional) (Deadline: 2/5/18)

Multilevel Interventions in Cancer Care Delivery: Follow-up to Abnormal Screening Tests (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, cervical, colorectal, or lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the patient, provider, clinical team, clinic, healthcare institution, or community setting levels. Appropriate applications for this FOA should propose to intervene at two or more levels, and measure outcomes at three or more levels, while accounting for interactions that occur between and across levels.

Applications due February 5, 2018

  Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01 Clinical Trial Optional) (Deadline: 2/5/18)

Oral Anticancer Agents: Utilization, Adherence, and Health Care Delivery (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage research grant applications to: (1) assess and describe the current state of oral anticancer medication utilization, delivery, and adherence; (2) identify structural, systemic, and psychosocial barriers to adherence; and (3) develop models and strategies to improve safe and effective delivery of these agents so that clinical outcomes are optimized. Applications should focus research questions on at least one of the following: specific cancer type; class of drugs; and/or groups subject to disparities (e.g., elderly populations, members of low socioeconomic groups, racial/ethnic minorities). Research may be focused at the patient (pediatric, adolescent, or adult), patient-caregiver, provider, health care team, or health care delivery system level, and may include intervention studies, observational studies, or mixed-methods studies. Observational studies should emphasize modifiable risk factors for future intervention research.

Applications due February 5, 2018

  Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional) (Deadlines: 2/5/18; 10/5/18; 6/5/19; 2/5/20; and 10/5/20)

Testing Interventions for Health-Enhancing Physical Activity (R01 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level physical activity intervention programs acting on at least two levels of the socio-ecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.

Applications due February 5, 2018; October 5, 2018; June 5, 2019; February 5, 2020; and October 5, 2020

  NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required) (Deadline: 2/12/18)

NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required)

The purpose of the NCI Mentored Clinical Scientist Career Development Award (K08) program is to prepare individuals for careers that have a significant impact on the health-related research needs of the nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. The NCI-sponsored K08 award is specifically designed to promote career development of clinical scientists from backgrounds that have been shown to be nationally underrepresented in health-related science and for those who are committed to a career in basic biomedical, behavioral or translational cancer research, including research on cancer health disparities. The expectation is that through this sustained period of research career development and training, awardees will develop enhanced research capabilities for cancer research careers and be better prepared to compete for research project grants (e.g. R03, R21, or R01) funding.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-18-337).

Applications due February 12, 2018

  Tobacco Regulatory Science (R01) (Deadline: 2/13/18; LOI due 30 days prior)

Tobacco Regulatory Science (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Applications due February 13, 2018 with an LOI due 30 days prior

  Tobacco Regulatory Science (R21) (Deadline: 2/13/18; LOI due 30 days prior)

Tobacco Regulatory Science (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to invite research project applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. 

Applications due February 13, 2018 with an LOI due 30 days prior

  Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed (Deadlines: 2/14/18; 7/10/18; and 10/8/18

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3) Clinical Trials Not Allowed

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the adoption and validation of molecular/cellular/imaging markers and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA also includes the validation of pharmacodynamic markers and markers of toxicity. Applicants to this FOA must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the assay(s) and marker(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance durability of anti-cancer responses, multiple assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously.

Applications due February 14, 2018; July 10, 2018; October 8, 2018

  Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) (Deadline: 2/15/18)

Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01)

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), encourages the submission of grant applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO-screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

Applications due February 15, 2018

  Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional) (Deadline: 2/16/18)

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

This FOA will not support phase III clinical trials.

Applications due February 16, 2018

  Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional) (Deadline: 2/16/18)

Developing Interventions for Health-Enhancing Physical Activity (R21/R33 - Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research aimed at developing multi-level physical activity intervention programs acting on at least two levels of the socioecological model and designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to two years (R21 phase) for research planning activities and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for optimizing the intervention and conducting larger-scale feasibility studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds.

Applications due February 16, 2018

  Examination of Survivorship Care Planning Efficacy and Impact (R21) (Deadline: 2/16/18)

Examination of Survivorship Care Planning Efficacy and Impact (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

Applications due February 16, 2018

  Biological Comparisons in Patient-Derived Models of Cancer (U01) (Deadline: 3/7/18)

Biological Comparisons in Patient-Derived Models of Cancer (U01)

The purpose of this FOA is to encourage applications wherein similarities and differences in the underlying biological mechanisms that drive cancer phenotype and response to perturbations between two or more patient-derived models of cancer originating from a common patient sample are delineated and compared.

Applications due March 7, 2018

  Request for Proposals in Leukemia Research (Deadline: 4/1/18)

Request for Proposals in Leukemia Research

This request for proposals (RFP) is to solicit innovative research in leukemia. Grants are offered to those requesting support for laboratory, translational, or clinical research related to acute leukemia. The Foundation is supporting leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of "when everyone survives."

Applications due April 1, 2018

  Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed) (Deadline: 4/5/18)

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) proposing research for commercial development of novel cancer-relevant technologies. The proposed research projects are expected to focus on the development of highly-innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care.

Applications should specify milestones relevant to both the development and commercialization of these technologies. This FOA complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating the path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches.

Clinical trials are not allowed for this FOA.

Applications due April 5, 2018

  The Pancreatic Cancer Detection Consortium (U01) (Deadline: 4/6/18)

The Pancreatic Cancer Detection Consortium (U01)

This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. This initiative addresses one of the four research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Pancreatic Ductal Adenocarcinoma.

The PCDC is intended to support research for the development and testing of new molecular and imaging biomarkers for identifying patients at high risk for PDAC (because of genetic factors or the presence of precursor lesions) who could be candidates for early intervention. The research will be conducted by individual multi-disciplinary research teams, hereafter called Units.

The Units will undertake studies on the following areas:

  • Identification and testing of biomarkers measurable in bodily fluids for early detection of PDAC or its precursor lesions;
  • Determine which pancreatic cysts are likely to progress to cancer;
  • Develop molecular- and/or imaging-based approaches for screening populations at high risk of PDAC;
  • Conduct biomarker validation studies; and
  • Collect longitudinal biospecimens for the establishment of a biorepository.

All Units are expected to participate in collaborative activities with other Units and share ideas, specimens and data within the Consortium.

Applications due September 21, 2017 OR April 6, 2018

  Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (Deadline: 5/14/18)

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities.

For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii.

Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

Applications due May 14, 2018

  Research to Improve Native American Health (R21 Clinical Trials Optional) (Deadline: 5/14/18)

Research to Improve Native American Health (R21 Clinical Trials Optional)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory developmental research to improve Native American (NA) health. Such research can include: conducting secondary analysis of existing data (such as databases that the Tribal Epidemiology Centers have collected); merge various sources of data to answer critical research questions; conduct pilot and feasibility studies; and/or assess and validate measures that are being developed and/or adapted for use in NA communities.

For the purposes of this FOA, the term 'Native Americans' includes the following populations: Alaska Native, American Indian, and Native Hawaiian. The term 'Native Hawaiian' means any individual whose ancestors were natives, prior to 1778, belonging to the area that now comprises the State of Hawaii.

Studies should: be culturally appropriate and result in promoting the adoption of healthy lifestyles; improve behaviors and social conditions and/or improve environmental conditions related to chronic disease; prevent or reduce the consumption of tobacco, alcohol, and other drugs; improve mental health outcomes; reduce risk of HIV infection; improve treatment adherence and/or health-care systems adopting standards of care to improve overall quality of life.

Applications due May 14, 2018

  Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21) (Deadline: 6/14/18)

Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant (R21) applications for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge.

The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed informatics method or algorithm must have a clear rationale on why it is novel and how it will benefit the cancer research field. Potential applicants who are interested in more downstream tool development, from prototyping to hardening and adaptation, should consult the other companion FOAs listed above.

Applications due June 14, 2018

  Sustained Support for Informatics Resources for Cancer Research and Management (U24) (Deadline: 6/14/18)

Sustained Support for Informatics Resources for Cancer Research and Management (U24)

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high-value informatics research resources to serve current and emerging needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on supporting activities necessary for improved user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs.

The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justifications for why the research resource should be maintained and how it has benefited and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and/or deep engagement between the resource and the targeted research community should be described.

Applications due June 14, 2018

National Institutes of Health (NIH)

Open AllClose All
  Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54) (Deadline: 1/26/18)

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)

This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations.

The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities.

January 26, 2018, LOI due 45 days prior

  Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers (Deadline: 2/5/18; 2/16/18)

Palliative Care Needs of Individuals with Rare Advanced Diseases and Their Family Caregivers

This funding opportunity announcement (FOA) seeks to expand knowledge and increase the evidence base for palliative care (PC) in advanced rare diseases, including rare cancers, and to improve physical and psychosocial well-being and quality of life among seriously ill individuals and their family caregivers.

Deadlines:

  Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival (Deadline: 2/5/18; 2/16/18)

Physical Activity and Weight Control Interventions Among Cancer Survivors: Effects on Biomarkers of Prognosis and Survival

This Funding Opportunity Announcement (FOA) encourages transdisciplinary and translational research that will identify the specific biological or biobehavioral pathways through which physical activity and/or weight control (either weight loss or avoidance of weight gain) may affect cancer prognosis and survival. Research applications should test the effects of physical activity, alone or in combination with weight control (either weight loss or avoidance of weight gain), on biomarkers of cancer prognosis among cancer survivors identified by previous animal or observational research on established biomarkers other than insulin/glucose metabolism, especially those obtained from tumor tissue sourced from repeat biopsies where available.

Because many cancer survivor populations will not experience recurrence but will die of comorbid diseases or may experience early effects of aging, inclusion of biomarkers of comorbid diseases (e.g., cardiovascular disease) and of the aging process are also sought. Applications should use experimental designs (e.g., randomized controlled clinical trials (RCTs), fractional factorial designs), and include transdisciplinary approaches that bring together behavioral intervention expertise, cancer biology, and other basic and clinical science disciplines relevant to the pathways being studied.

Deadlines

  Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required) (Deadline: 2/14/18; 6/28/18; 10/11/18)

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required)

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Deadline:

  • February 14, 2018
  • June 28, 2018
  • October 11, 2018
  Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18-No Independent Clinical Trials) (Deadline: 3/6/18; 3/6/19)

Short-term Mentored Career Enhancement Awards for Mid-Career Investigators to Integrate Basic Behavioral and Social Sciences (K18-No Independent Clinical Trials)

This Funding Opportunity Announcement (FOA) encourages applications for short-term mentored career development (K18) awards that improve synergies among researchers in basic and applied behavioral-social sciences, human subjects and model animals settings; and biomedical and behavioral-social sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (FOA #).

Deadline:

  • March 6, 2018
  • March 6, 2019
  Bioengineering Research Partnerships (U01 Clinical Trial Optional) (Deadline: 5/8/18; 9/13/18)

Bioengineering Research Partnerships (U01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.  The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.  The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.

Deadline:

  • May 8, 2018
  • September 13, 2018
  NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) (Deadline: 7/19/18)

NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)

The purpose of this Funding This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials.

The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk, but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

Deadline: July 19, 2018

  Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science.

Deadline: Standard Dates Apply

  End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses (Deadline: Standard Dates Apply)

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) with Serious Illnesses

The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 – 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Deadline: Standard Dates Apply

  Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

Deadline: Standard Dates Apply

  Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (Deadline: Standard Dates Apply)

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Deadline: Standard Dates Apply

  Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Mechanisms, Models, Measurement, & Management in Pain Research (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

Deadline: Standard Dates Apply

  NCI Mentored Research Scientist Development Award to Promote Diversity (K01) (Deadline: Standard Dates Apply)

NCI Mentored Research Scientist Development Award to Promote Diversity (K01)

The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the pool of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor.

The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be nationally underrepresented in health-related sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA.

Deadline: Standard Dates Apply

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Deadline: Standard Dates Apply

  Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional) (Deadline: Standard Dates Apply)

Target Assessment, Engagement and Data Replicability to Improve Substance Use Disorders Treatment Outcomes (R21/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is part of an NIH initiative known as Collaborative Research on Addiction at NIH (CRAN). Areas supported by this FOA include research to generate and conduct preliminary tests of targeted addiction treatment to address multiple substances, which may include alcohol, tobacco and other drug use (ATOD).

This FOA encourages applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of alcohol, tobacco and other drug use, and clear hypotheses about how a treatment directed at changing the target can lead to clinical benefits.

Studies of novel treatments include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches. This FOA provides support for up to two years (Phase I; R21) for protocol development, target identification and studies to confirm target engagement (i.e., link targets with tangible outcomes); followed by up to 3 years of support (Phase II; R33) for replication studies of addiction treatment across 2 or more settings. Specifically, this latter phase will focus on clinical trials that apply the target in a treatment setting (development, refinement, and/or adaptation) to evaluate the feasibility of conducting a larger trial.

Deadline: Standard Dates Apply

  The Health of Sexual and Gender Minority (SGM) Populations (Deadline: Standard Dates Apply)

The Health of Sexual and Gender Minority (SGM) Populations

The National Institutes of Health (NIH) is committed to supporting research that will increase scientific understanding of the health status of diverse population groups and thereby improve the effectiveness of health interventions and services for individuals within those groups. Priority is placed on understudied populations with distinctive health risk profiles. This funding opportunity announcement (FOA) focuses on sexual and gender minority (SGM) populations, including lesbian, gay, bisexual, transgender, and intersex populations. Basic, social, behavioral, clinical, and services research relevant to the missions of the sponsoring Institutes and Centers may be proposed.

Deadline: Standard Dates Apply

  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Foundation for Women's Cancer Prize For Outstanding Gynecologic Cancer Researcher (Deadline: 11/27/17)

Foundation for Women's Cancer Prize For Outstanding Gynecologic Cancer Researcher

This new Prize for Outstanding Gynecologic Cancer Researcher is a $10,000 prize, awarded to an individual in recognition of his or her outstanding contributions to research improving the care of women with gynecologic cancer. The selected awardees will have made important contributions that improve gynecologic cancer patient care, including the early detection, treatment or prevention of gynecologic cancers. The award will be made to the individual rather than his/her institution.  Individuals can apply for this prize or nominators can propose potential candidates by filling out the application on the following page.

Applications due November 27, 2017

  Scientific Scholar Award (Marsha Rivkin Center for Ovarian Cancer Research) (Deadline: 12/1/17)

Scientific Scholar Award (Marsha Rivkin Center for Ovarian Cancer Research)

The Rivkin Center Scientific Scholar Award is intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. Research funding for ovarian cancer is comparatively low, which discourages talented laboratory scientists and physicians from directing their careers toward ovarian cancer. The Scientific Scholar Award provides the funds for the best and brightest minds to have an opportunity to begin a career in ovarian cancer research.

Applications due December 1, 2017

  AACR Gertrude B. Elion Cancer Research Award (Deadline: 12/5/17)

AACR Gertrude B. Elion Cancer Research Award

The AACR Gertrude B. Elion Cancer Research Award represents a joint effort to encourage and support tenure-eligible junior faculty. The research proposed for funding must focus on research in cancer etiology, diagnosis, treatment, or prevention and may be basic, translational, or clinical in nature.

Applications due December 5, 2017

  Appendix A: NASA Research and Technology Development to Support Crew Health and Performance in Space Exploration Missions (Deadline for Step 2: 12/5/17)

Appendix A: NASA Research and Technology Development to Support Crew Health and Performance in Space Exploration Missions

Ground-based research in the use of archived irradiated tissue samples or those from ongoing studies should address the following specific research focus areas (only those in cancer listed below):

 

  1. Examination of available tissue samples for evidence of dose-dependent, common pathway activation (e.g., inflammation) across tissues that address multiple risk areas (cancer, CNS, and cardiovascular disease) and inform identification of biomarkers and radioprotective countermeasures.

    Deliverables: Research results supporting identification of cross-risk biomarkers and countermeasures.
     
  2. Examination of available tissues from chronically irradiated animals, including bone marrow and/or blood samples, to evaluate immune and hematopoietic function using clinically relevant measures.

    Deliverables: Research evidence supporting risk characterization of potential deficits to the hematopoietic/immune system induced by chronic radiation exposure.
     
  3. Advanced molecular characterization of high-mass, high-energy (HZE) and mixed-field radiation-induced tumors, supporting the extrapolation of animal data to human datasets to inform cancer morbidity and mortality projections, and biomarker and countermeasure identification. Characterization of tumors of the lung, colon, stomach, breast, ovary, bladder, and liver are of interest for this topic.

    Deliverables: Research results supporting extrapolation of animal data to humans, as required to inform cancer morbidity and mortality projections, and biomarker and countermeasure identification.

Proposals due:

  • Step1: September 12, 2017
  • Step 2: December 5, 2017
  Appendix B: NASA Human Research Program Omnibus Opportunity (Deadline for Step 2: 12/5/17)

Appendix B: NASA Human Research Program Omnibus Opportunity

To expedite progress in various research areas in a short period of time, NASA is requesting proposals for short-term investigations or technology development projects that provide innovative approaches to any of the risks and associated knowledge gaps contained in the Integrated Research Plan (IRP) of the Human Research Program (HRP). Risks and gaps identified in the IRP included, but are not limited to, the following:

  1. Exploration Medical Capability (includes risks posed by inflight medical conditions such as renal stones, and bone fracture)
  2. Human Factors and Behavioral Performance (includes risks such as behavior, cognitive, or psychiatric disorders; sleep disorders; failures in interpersonal communication, leadership, or training; or problems caused by inadequate design of habitats, robotics, or human-computer interaction)
  3. Human Health Countermeasures (includes measures for addressing proper nutrition, cardiac health, bone health, and altered immune response)
  4. Space Radiation (includes risks posed by radiation such as cancer, and damage to the central nervous system)

Proposals due:

  • Step1: September 12, 2017
  • Step 2: December 5, 2017
  CONquer canCER Now Award (Deadlines: Full Proposal by 12/7/17; LOI by 9/7/17; )

CONquer canCER Now Award

By specifically targeting promising early-career scientists and providing critically needed "seed" money for innovative projects, Concern Foundation supports development of the next generation of cancer researchers and thus promotes progress in understanding cancer biology and improved approaches to cancer.

**Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology**

Concern will not fund clinical trials, cancer epidemiology, or behavioral studies.

LOI due September 7, 2017

Full Proposal due December 7, 2017

  Interventional Oncology/Immuno-Oncology Research Grant / SIO Research Grant (Deadline: 12/15/17)

Interventional Oncology/Immuno-Oncology Research Grant / SIO Research Grant

The Society of Interventional Oncology / Immuno-Oncology Research Grant, generously sponsored by Biocompatibles UK Ltd., is designed to fund research evaluating immune stimulation of interventional oncologic therapies, combination approaches to improve clinical outcome, and an improved understanding of the underlying mechanisms as to how our different therapies influence both adaptive and innate immunity, as well as underlying inflammation and tumorigenesis.

Application due December 15, 2017

  Young Investigator Grants (Deadline: 12/15/17)

Young Investigator Grants

Alex's Lemonade Stand Foundation (ALSF) evolved from the front yard lemonade stand of cancer patient Alexandra "Alex" Scott (1996 - 2004) into a national fundraising movement to find a cure for all childhood cancers. The Young Investigator Grants are designed to support scientists during their fellowship training or early in their research careers.

Demonstration of outstanding mentorship and demonstration of a career plan that shows commitment to pediatric cancer investigation are critical components o f a successful application. Young Investigator Grants are 3 year awards designed to support scientists in the early stages of their research careers, such as postdoctoral or clinical fellows. Outstanding mentorship and demonstration of a career plan that shows commitment to pediatric cancer investigation are critical components of a successful application.

Applications due December 15, 2017

  Lung Cancer Discovery Award (Deadline: 12/21/17)

Lung Cancer Discovery Award

Investigators with projects that focus on understanding the impact of lung cancer in women are encouraged to apply, areas of interest include:

  • Novel examination of tumor testing
  • Pilot Studies examining new treatment options
  • Lung Cancer in Never-Smokers
  • Patient Centered Outcomes, Patient Engagement and Health Services Research


Projects are expected to have a direct impact on early detection/treatment methods or provide a clear conceptual or experimental foundation for future development. The preference is for studies that are likely to result in patient benefit in the near future.

Applications due December 21, 2017

  AACR NextGen Grants for Transformative Cancer Research (Deadline: 1/8/18; LOI due 9/22/17)

AACR NextGen Grants for Transformative Cancer Research

The proposed research must represent a highly innovative approach to a major contemporary challenge in cancer research. The funded projects must have the potential to lead to groundbreaking discoveries in the field, and transform our understanding of the tumorigenesis process and/or our ability to treat, detect, or prevent cancer. The research can be in any area of basic, translational, or clinical science.

Applications due January 8, 2018; LOI Deadline: September 22, 2017

  MRA Team Science Awards (Deadline: 1/9/18)

MRA Team Science Awards

Awards for team science are designed to foster a collaborative research process and promote transformational melanoma research advances with the potential for rapid clinical translation. Multidisciplinary teams will receive funding to support projects with the potential to lead to transformative advances in prevention, detection, diagnosis, staging and/or treatment of melanoma.

Team Science Awards have a collaborative and multidisciplinary emphasis, involving meaningful collaboration between participants. LOIs must include a description of the nature of and rationale for the proposed collaboration, the specific role of all PIs and the Young Investigator, and synergistic opportunities derived from the team proposed. Evidence of prior productive collaborations between members of the team is also useful.

Full Proposal due January 9, 2018

  Collaborative Pediatric Cancer Research Awards Program: Grant Funding Opportunity In Pediatric Oncology - Independent Investigator and Consortium Grant (Deadline: 1/10/18)

Collaborative Pediatric Cancer Research Awards Program: Grant Funding Opportunity In Pediatric Oncology - Independent Investigator and Consortium Grant

Collaborative Pediatric Cancer Research Awards Program members include Rally Foundation, Bear Necessities, Arms Wide Open Childhood Cancer Foundation, and The Truth 365, national non-profit organizations dedicated to eliminating childhood cancer through innovative research in pediatric oncology. Members of the Collaboration may choose to co-fund or individually fund an applicant.

Rally funds research in the following areas:

  • Under-studied cancer types
  • Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials
  • Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
  • Quality of life and survivorship research proposals

Full Proposal due January 10, 2018

  Discovery Grant (Deadline: 1/10/18)

Discovery Grant

The ABTA Discovery Grants are intended to encourage the development of new approaches to the diagnosis and treatment of brain tumors. By providing funding through its Discovery Grants, the ABTA seeks to support high-risk/high-impact projects with the potential to change current diagnostic or treatment paradigms for adult and pediatric brain tumor care. These grants specifically encourage novel research by allowing researchers to conduct the early scientific studies needed to secure additional/future funding for their projects. Additionally, investigators from sciences outside traditional biological fields are encouraged to apply. The development of new diagnostic and therapeutic approaches advances the understanding and treatment of brain tumors, and increases the potential for improving, extending and ultimately saving the lives of those living with a brain tumor diagnosis.

Full Proposal due January 10, 2018

  Desmoid Tumor Research Foundation (Deadline: 1/12/18)

Desmoid Tumor Research Foundation

The Desmoid Tumor Research Foundation, Inc. (“DTRF”) funds research that will advance the current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure. DTRF is the only foundation in the world dedicated to facilitating and funding research for a cure for desmoid tumors.

We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research. Research proposals with additional sources of funding support are particularly desirable. Researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF’s future grant review cycle, as well as to exert best efforts to attend the annual fall International DTRF Desmoid Tumor Research Workshop

Applications due January 12, 2018

  Hope Funds for Cancer Research-Postdoctoral Fellowship (Full application Deadline: 1/14/18; Pre-Applications Deadline: 9/15/17)

Hope Funds for Cancer Research-Postdoctoral Fellowship

The Hope Funds for Cancer Research is offering fellowships to postdoctoral scientists who propose to work on highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS.

Pre-Applications due September 15, 2017; Application due January 14, 2018

  CORE Grants: AHNS/AAO-HNSF Translational Innovator Combined Award (Deadline: 1/16/18)

CORE Grants: AHNS/AAO-HNSF Translational Innovator Combined Award

The purpose of this award is to support contemporary basic or clinical research focused on neoplastic disease of the head and neck for full time academic surgeons to promote novel translational research preferably with biomarker ideas.

Applications due January 16, 2018

  Stand Up To Cancer (SU2C) Dream Team Translational Research Grant (Deadline: Invited Full Proposal by 1/16/18; LOI by 9/5/17)

Stand Up To Cancer (SU2C) Dream Team Translational Research Grant

The Stand Up To Cancer Dream Team Translational Research Grant will fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.

The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.

LOI due September 5, 2017

Invited full proposals due January 16, 2018

  Fanconi Anemia Research Fund (Deadline: 2/2/18)

Fanconi Anemia Research Fund

The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities:

  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders.
  • To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life.
  • To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.

Applications due February 02, 2018

  Collaborative Pediatric Cancer Research Awards Program (Deadline: 2/22/18)

Collaborative Pediatric Cancer Research Awards Program

Rally funds research in the following areas:

  • Under-studied cancer types
  • Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials
  • Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals
  • Quality of life and survivorship research proposals

Full proposals due February 22, 2018

  Childhood Cancer Research Seed Grants (Deadline: LOI due 10/19/17; Applications due 3/15/18)

Childhood Cancer Research Seed Grants

The Foundation invites applications for its seed grant program, which provides funding to conduct innovative, cutting edge investigations, with preferences going toward less common childhood cancers. In addition, more projects that focus on Opsoclonus-Myoclonus Syndrome (OMS) will be considered.

The Foundation is interested in principal investigators who will join it in taking risks, pushing for new solutions, and harnessing the transformative power of science in their research in the following broad areas:

  • Mechanisms of Disease
  • Genetics
  • Preclinical Models
  • Biomarkers and Surrogate Markers
  • Prognostic Factors
  • Diagnosis
  • Innovative Clinical Therapeutic Trials
  • Minimal Residual Disease Detection
  • Treatment
  • Supportive Care and Prevention
  • Amelioration of Long-Term Effects of Therapy

By seeking answers and adding to the body of knowledge in pediatric cancer research, The Pablove Foundation will make an impact on the lives of children who are affected by childhood cancer.

LOI Due October 19, 2017, Applications due March 15, 2018

  Innovation Grant (Alex’s Lemonade Stand Foundation for Childhood Cancer) (Deadline: 4/2/18)

Innovation Grant (Alex’s Lemonade Stand Foundation for Childhood Cancer)

The Innovation Grant is designed to provide critical and significant seed funding for experienced investigators with a novel and promising approach to finding causes and cures for childhood cancers.

Applications due April 2, 2018

  Surgical Disparities Research (R01) (Deadline: 6/7/18)

Surgical Disparities Research (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support investigative and collaborative research focused on understanding and addressing disparities in surgical care and outcomes, in minority and health disparity populations. While the goal is to better understand and explore effectiveness of clinical intervention approaches for addressing surgical disparities, this initiative will also seek to identify multi-level strategies at the institutional and systems level.

Applications due June 7, 2018

  Adenoid Cystic Carcinoma Research Foundation (Deadline: Continuous)

Adenoid Cystic Carcinoma Research Foundation

Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.

Deadline continuous

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline: Continuous)

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline: Continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

  Women's Cancer Research Grants (Deadline: Continuous)

Women's Cancer Research Grants

The FWC continues to seek additional funding to support expanded research priorities. Of special importance is increased funding for cervical, uterine, primary peritoneal, vaginal and vulvar cancer research. Additionally, the Foundation is seeking funding for a series of new types of research opportunities:

  • Post-Doctoral Fellowship grants: These grants are intended to attract and support promising young scientists and clinician/scientists to ensure the next generation of skilled researchers dedicated to gynecologic cancer research.
  • Career Development Awards: These grants are similar to the NIH CDA, K series awards, and are awarded to applicants who wish to further develop their careers in gynecologic cancer biomedical, behavioral or clinical research
  • Paired grants: Junior investigators would join with senior investigators for grants lasting two to three years.
  • Innovative grants: These grants would provide funding for creative and imaginative research projects that show promise for significant breakthroughs, but have not been sufficiently advanced or developed to receive support through traditional funding channels.
  • Extension of the current, highly successful stimulus or “seed” grant program to include all gynecologic cancers, and the opportunity for competitive renewals at the conclusion of the one-year research grant.

Deadline continuous

Other Peer Review

Open AllClose All
  Kidney Cancer Research Program Concept Award (Deadline: 1/4/18)

Kidney Cancer Research Program Concept Award

The FY17 KCRP Concept Award supports highly innovative, untested, potentially groundbreaking novel concepts in kidney cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. Preliminary data are not allowed. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. Applications must describe how the new idea will enhance the existing knowledge of kidney cancer or develop an innovative and novel course of investigation. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research.

Applications due January 4, 2018

  Kidney Cancer Research Program Idea Development Award (Deadline: 1/4/18)

Kidney Cancer Research Program Idea Development Award

The FY17 KCRP Idea Development Award is intended to support innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the KCRP vision of eliminating kidney cancer. The research project should include a well-formulated, testable hypothesis based on strong scientific rationale and a well-developed and articulated research approach relevant to active duty Service members, Veterans, other military beneficiaries, and the American public. Personnel on the proposed team should have a strong background in kidney cancer research.

Applications due January 4, 2018

  Kidney Cancer Research Program Translational Research Partnership Award (Deadline: 1/4/18)

Kidney Cancer Research Program Translational Research Partnership Award

The FY17 KCRP Translational Research Partnership Award mechanism supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in kidney cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty level (or equivalent) investigators to address a central problem or question in kidney cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged. At least one member of the partnership must have experience either in kidney cancer research or kidney cancer patient care. Inclusion of experts from outside of the kidney cancer field is encouraged. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.

Applications due January 4, 2018

Top